1. Home
  2. CISO vs CTXR Comparison

CISO vs CTXR Comparison

Compare CISO & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CISO Global Inc.

CISO

CISO Global Inc.

HOLD

Current Price

$0.49

Market Cap

20.3M

Sector

Technology

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.82

Market Cap

18.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISO
CTXR
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.3M
18.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CISO
CTXR
Price
$0.49
$0.82
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
509.7K
1.6M
Earning Date
11-13-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,743,266.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.63
52 Week High
$1.70
$3.44

Technical Indicators

Market Signals
Indicator
CISO
CTXR
Relative Strength Index (RSI) 47.48 34.64
Support Level $0.46 $0.82
Resistance Level $0.57 $0.99
Average True Range (ATR) 0.04 0.07
MACD 0.01 0.00
Stochastic Oscillator 40.31 10.78

Price Performance

Historical Comparison
CISO
CTXR

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: